Friday, February 1, 2019

Celgene Corp, which is being bought by Bristol-Myers Squibb Co, reported a better-than-expected fourth-quarter profit on Thursday, driven mainly by higher sales of psoriasis drug Otezla.


from Reuters: Health News https://reut.rs/2MGE8Yw

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner